Displaying drugs 7626 - 7650 of 8028 in total
OBE101
OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management...
Investigational
Matched Description: … repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of …
Pipendoxifene
ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment for metastatic breast cancer.
Investigational
Matched Description: … modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of …
TD-2749
TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
Investigational
Matched Description: … TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug …
Lonidamine
Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs.
Investigational
Matched Description: … Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting …
Bizalimogene ralaplasmid
Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2).
Investigational
Matched Description: … NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of …
Reproxalap
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
Investigational
Matched Description: … [L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome …
Carbenoxolone
An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]
Experimental
Matched Description: … It is used for the treatment of digestive tract ulcers, especially in the stomach. …
RPI-78M
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
Investigational
Matched Description: … RPI-78M is being developed for the treatment of multiple sclerosis (MS). …
Bicuculline
Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.
Experimental
Matched Description: … Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. …
Onatasertib
Onatasertib (CC-223) has been used in trials studying the treatment and basic science of Multiple Myeloma, Glioblastoma Multiforme, HepatoCellular Carcinoma, Non-small Cell Lung Cancer, and Diffuse Large B-Cell Lymphoma, among others.
Investigational
Matched Description: … Onatasertib (CC-223) has been used in trials studying the treatment and basic science of Multiple Myeloma …
BMS-986104
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
Investigational
Matched Description: … Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of …
Iopofosine I-131
Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).
Investigational
Matched Description: … Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of …
Ontuxizumab
Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1). It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and Clinical Evaluation).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research …
Simurosertib
Simurosertib is under investigation in clinical trial NCT03261947 (A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors).
Investigational
Matched Description: … investigation in clinical trial NCT03261947 (A Study to Evaluate the Safety, Tolerability, and Activity of …
Zofin
Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the addition of other substances .
Investigational
Matched Description: … which is manufactured in a way that retains the naturally occurring microRNAs without the addition of …
A166
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.
Investigational
Matched Description: … A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) …
Cry5B
Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium Bacillus thuringiensis. With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal infections.[A259372, A259377]
Investigational
Matched Description: … With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal …
Oxogluric acid
Oxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. In the United States a phase I clinical trial is investigating whether oxogluric acid precursors found in nutritional supplements can benefit patients with the metabolic disorder propionic acidemia. Oxogluric...
Experimental
Investigational
Nutraceutical
Matched Description: … decreased synthesis of muscle protein that is often seen post-surgery. ... in the Krebs cycle as an intermediate, is involved in transamination reactions during the metabolism of ... Several experimental studies have also shown that administration of oxogluric acid helped attenuate the …
DP-VPA
DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.
Investigational
Matched Description: … DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA …
Pardoprunox
Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease. Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.
Investigational
Matched Description: … Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced …
Fenobam
Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome).
Investigational
Matched Description: … under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of …
2'-fluoro-5-ethylarabinosyluracil
2'-fluoro-5-ethylarabinosyluracil (FAU) has been used in trials studying the treatment of Small Intestine Lymphoma, Stage IV Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Splenic Marginal Zone Lymphoma, and Recurrent Mantle Cell Lymphoma, among others.
Investigational
Matched Description: … 2'-fluoro-5-ethylarabinosyluracil (FAU) has been used in trials studying the treatment of Small Intestine …
ONT-093
ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
Investigational
Matched Description: … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). …
ONO-2952
ONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)).
Investigational
Matched Description: … ONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 …
Red blood cell-encapsulated L-asparaginase
Red blood cell-encapsulated L-asparaginase is Asparaginase Escherichia coli encapsulated inside donor-derived red blood cells, which target cancer cells capable of altering asparagine and glutamine metabolism. It is being investigated in cancers.
Investigational
Matched Description: … Escherichia coli] encapsulated inside donor-derived red blood cells, which target cancer cells capable of …
Displaying drugs 7626 - 7650 of 8028 in total